D-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotá

dc.contributor.advisorCuervo Maldonado, Sonia Isabelspa
dc.contributor.authorDomínguez Gómez, Carolinaspa
dc.contributor.researchgroupGreicah Grupo en Enfermedades Infecciosas en Cáncer y Alteraciones Hematológicasspa
dc.coverage.cityBogotáspa
dc.date.accessioned2022-02-10T20:04:20Z
dc.date.available2022-02-10T20:04:20Z
dc.date.issued2022-01-19
dc.descriptionilustraciones, gráficas, tablasspa
dc.description.abstractLos pacientes con neoplasias hematológicas son huéspedes susceptibles para el desarrollo de infección fúngica invasora. Actualmente, se dispone de estrategias de profilaxis antifúngica, esquemas de tratamiento antimicótico y, se reconoce como uno de los principales factores de riesgo, la neutropenia profunda y prolongada. El D-index acumulado es un parámetro cuantitativo diseñado en 2009, que determina la severidad de la neutropenia, evaluando el déficit acumulativo de neutrófilos <500 células/μL, desde el inicio del episodio hasta la aparición de la primera manifestación clínica de infección. Objetivo general: El presente estudio propone estimar la fuerza de asociación del D-index acumulado, para el desarrollo de infección fúngica invasora, en pacientes con leucemia linfoblástica aguda. Materiales y métodos: Estudio de casos y controles, en mayores de 18 años, con leucemia linfoblástica aguda, admitidos entre 2009 y 2019 en el Instituto Nacional de Cancerología, para quimioterapia de inducción y consolidación. Resultados: Se incluyeron 156 pacientes, quienes aportaron 264 ciclos de quimioterapia, como unidad de análisis. Se construyó un modelo GEE para analizar datos longitudinales correlacionados. En este modelo se incluyeron 3 variables cuantitativas continuas: edad (años), el D-index y la neutropenia profunda (días). Sólo el D-index demostró ser la variable significativa, con un OR= 1,000304 (IC 95% 1.0002 – 1.0004); p > 0,001. Conclusiones: El D-index acumulado se asocia con el desarrollo de IFI en pacientes con leucemia linfoblástica aguda, con aumento del OR conforme aumenta el D-index, siendo mayor cuando el valor de D-index supera el valor de 4.208. (Texto tomado de la fuente).spa
dc.description.abstractPatients with hematologic malignancies are susceptible hosts for the development of invasive fungal infection. Currently, there are antifungal prophylaxis strategies, antifungal treatment schemes, and profound and prolonged neutropenia is recognized as one of the main risk factors. The cumulative D-index is a calculated parameter designed in 2009, which determines the severity of neutropenia, evaluating the cumulative deficit of neutrophils <500 cells/μL, from the start of the episode until the appearance of the first clinical manifestation of infection. Objective: The present study proposes to estimate the strength of association of the accumulated D-index, for the development of invasive fungal infection, in patients with acute lymphoblastic leukemia. Methods: Case-control study, in patients over 18 years of age, with acute lymphoblastic leukemia, admitted between 2009 and 2019 at the National Cancer Institute, for induction and consolidation chemotherapy. Results: 156 patients were included, who provided 264 cycles of chemotherapy, as the unit of analysis. A GEE model was built to analyze correlated longitudinal data. This model includes 3 continuous quantitative variables: age (years), the D-index and profound neutropenia (days). Only the D-index stood out as the significant variable, with an OR= 1.000304 (95% CI 1.0002 – 1.0004); p > 0.001. Conclusions: The accumulated D-index is associated with the development of IIF in patients with acute lymphoblastic leukemia, with an increase in the OR as the D-index increases, being higher when the value of D-index exceeds the value of 4.208.eng
dc.description.degreelevelEspecialidades Médicasspa
dc.description.degreenameEspecialista en Medicina Internaspa
dc.description.methodsEstudio de casos y controles, no pareado.spa
dc.description.notesIncluye anexosspa
dc.description.researchareaInfecciones fúngicas en pacientes con cáncerspa
dc.format.extentxiii, 34 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/80937
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Medicina Internaspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Internaspa
dc.relation.indexedBiremespa
dc.relation.referencesShariati A, Moradabadi A, Chegini Z, Khoshbayan A, Didehdar M. An overview of the management of the most important invasive fungal infections in patients with blood malignancies. Vol. 13, Infection and Drug Resistance. Dove Medical Press Ltd.; 2020. p. 2329–54.spa
dc.relation.referencesAntoniadou A, Giamarellou H. Fever of Unknown Origin in Febrile Leukopenia. Vol. 21, Infectious Disease Clinics of North America. 2007. p. 1055–90.spa
dc.relation.referencesHsu LY, Lee DG, Yeh SP, Bhurani D, Khanh BQ, Low CY, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: A prospective observational study. Clinical Microbiology and Infection. 2015 Jun 1;21(6):594.e7-594.e11.spa
dc.relation.referencesFernández-Cruz A, Lewis RE, Kontoyiannis DP. How long do we need to treat an invasive mold disease in hematology patients? factors influencing duration of therapy and future questions. Clinical Infectious Diseases. 2020 Aug 1;71(3):685–92.spa
dc.relation.referencesPeter Donnelly J, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clinical Infectious Diseases. 2020 Sep 15;71(6):1367–76.spa
dc.relation.referencesStohs E, Zimmer A. An Approach to Suspected Invasive Fungal Infection in Patients with Hematologic Malignancy and HCT Recipients with Persistent Neutropenic Fever Despite Mold-Active Prophylaxis. Vol. 14, Current Fungal Infection Reports. Springer; 2020. p. 89–98.spa
dc.relation.referencesLien MY, Chou CH, Lin CC, Bai LY, Chiu CF, Yeh SP, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study. PLoS ONE. 2018 Jun 1;13(6).spa
dc.relation.referencesNucci M, Anaissie E. How I Treat How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. 2014; 124(26):3858-69.spa
dc.relation.referencesPagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R, et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Vol. 31, Blood Reviews. Churchill Livingstone; 2017. p. 17–29.spa
dc.relation.referencesKubo H, Imataki O, Kubo YH, Uemura M, Kadowaki N. c-D-index is a risk factor for prolonged febrile neutropenia during chemotherapy in patients with acute myeloid leukemia. International Journal of Clinical Oncology. 2019 May 15;24(5):590–5.spa
dc.relation.referencesPortugal RD, Garnica M, Nucci M. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. Journal of Clinical Oncology. 2009 Aug 10;27(23):3849–54.spa
dc.relation.referencesYılmaz G, Coşkun B, Elhan A, Azap A, Akan H. D-index: Febril nötropenik hastalarda ınvazif mantar enfeksiyonlarının tanımlanmasında yeni bir skorlama sistemi. Turkish Journal of Hematology. 2016;33(2):102–6.spa
dc.relation.referencesInstituto Nacional de Cancerología – ESE. Anuario estadístico 2017. Volumen 15.spa
dc.relation.referencesBajpai VK, Khan I, Shukla S, Kumar P, Rather IA, Park YH, et al. Invasive Fungal Infections and Their Epidemiology: Measures in the Clinical Scenario. Vol. 24, Biotechnology and Bioprocess Engineering. Korean Society for Biotechnology and Bioengineering; 2019. p. 436–44.spa
dc.relation.referencesKo BS, Chen WT, Kung HC, Wu UI, Tang JL, Yao M, et al. 2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. Vol. 51, Journal of Microbiology, Immunology and Infection. Elsevier Ltd; 2018. p. 287–301.spa
dc.relation.referencesCamplesi Junior M, Silva HM, Arantes AM, Costa CR, Ataides FS, Silva TC, et al. Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital. Revista da Sociedade Brasileira de Medicina Tropical. 2017;50(1):80–5.spa
dc.relation.referencesLee SY, Yeo CL, Lee WH, Kwa AL, Koh LP, Hsu LY. Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in Singapore. BMC Research Notes. 2011;4.spa
dc.relation.referencesVusirikala M, Supportive care in hematologic malignancies. Wintrobe’s Clinical Hematology. 2009;1747–90.spa
dc.relation.referencesCooper B, Dubberke ER, Morris Engemann A, Freifeld AG, Greene JN, Ito JI, et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(7):882-913.spa
dc.relation.referencesDouglas AP, Slavin MA. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field. Expert Rev Anti Infect Ther. 2016;14(12):1165-1177.spa
dc.relation.referencesNicolato A, Nouér SA, Garnica M, Portugal R, Maiolino A, Nucci M. Invasive fungal diseases in patients with acute lymphoid leukemia. Leukemia and Lymphoma. 2016;57(9):2084–9.spa
dc.relation.referencesWarnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control Journal of Antimicrobial Chemotherapy. 1998;41:95–105.spa
dc.relation.referencesBodey GP, Buckley M, Sathe YS, Freireich EJ, Bethesda M. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328-40.spa
dc.relation.referencesGerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984 Mar;100(3):345-51.spa
dc.relation.referencesSipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer. 2005 Mar 15;103(6):1103-13.spa
dc.relation.referencesAbers MS, Ghebremichael MS, Timmons AK, Warren HS, Poznansky MC, Vyas JM. A Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis. Open Forum Infect Dis. 2016;3(1):ofw036.spa
dc.relation.referencesNatarajan SK, Narayan S, Liu Yin JA. Update on the Management of Febrile Neutropenia. European Oncology & Haematology, 2011;7(4):263-269spa
dc.relation.referencesWalsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013; 2013 (1): 423–427.spa
dc.relation.referencesPortugal RD, Garnica M, Nucci M. D-index and Prediction of Infection. Biol Blood Marrow Transplant 2010; 16: 1608.spa
dc.relation.referencesGarnica M, Sinhorelo A, Madeira L, Portugal R, Nucci M. Diagnostic-driven antifungal therapy in neutropenic patients using the D-index and serial serum galactomannan testing. Brazilian Journal of Infectious Diseases. 2016;20(4):354–9.spa
dc.relation.referencesKanda Y, Kimura S-I, Iino M, Fukuda T, Sakaida E, Oyake T, et al. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol. 2020;38(8):815-822.spa
dc.relation.referencesKimura S ichi, Kanda Y, Iino M, Fukuda T, Sakaida E, Oyake T, et al. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial. International Journal of Infectious Diseases. 2020;100:292–7.spa
dc.relation.referencesKimura S ichi, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Yoshino N, et al. Impact of neutropenia evaluated in terms of the D-index on invasive fungal disease while on empiric or preemptive antifungal treatment strategy in the early phase after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2020 Dec;22(6):e13409.spa
dc.relation.referencesLiang KY, Zeger SL. Longitudinal data analysis using generalized linear models Biometrika. 1986; 73(1):13–22spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/spa
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.decsMycoseseng
dc.subject.decsMicosisspa
dc.subject.decsPrecursor Cell Lymphoblastic Leukemia-Lymphomaeng
dc.subject.decsLeucemia-Linfoma Linfoblástico de Células Precursorasspa
dc.subject.decsNeutropenia Febrilspa
dc.subject.decsFebrile Neutropeniaeng
dc.subject.proposalD-indexspa
dc.subject.proposalD-indexeng
dc.subject.proposalInfección fúngica invasoraspa
dc.subject.proposalFactores de riesgospa
dc.subject.proposalNeutropeniaspa
dc.subject.proposalLeucemia linfoblástica agudaspa
dc.subject.proposalInvasive fungal infectioneng
dc.subject.proposalRisk factorseng
dc.subject.proposalNeutropeniaeng
dc.subject.proposalAcute lymphoblastic leukemiaeng
dc.titleD-index como factor de riesgo para infección fúngica invasora, en pacientes con leucemia linfoblástica aguda de un centro hematológico de referencia de Bogotáspa
dc.title.translatedD-index as a risk factor for invasive fungal infection in patients with acute lymphoblastic leukemia from a reference hematology center in Bogotáeng
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1110470021.2022.pdf
Tamaño:
1.42 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Especialidad en Medicina Interna

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
3.98 KB
Formato:
Item-specific license agreed upon to submission
Descripción: